Research Article

Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry

Volume: 28 Number: 3 June 28, 2025

Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry

Abstract

The combination of entecavir (ETV) and tenofovir (TEV), nucleos(t)ide analogs (NUCs), is advised as first-line treatment for people suffering from multidrug-resistant hepatitis B due to their favorable safety profile, low side-effect rate, and high genetic barrier. This study reports the fabrication of a novel cross-linked ethylenediamine sulfonamide polymer resin (EDASP) and graphene (Gr)-modified carbon paste electrodes (CPE) for the simultaneous determination of the anti-HBV drugs ETV and TEV in bulk and dosage form by differential pulse voltammetry (DPV). The electrodes were specified through cyclic voltammetry, Fourier transform infrared (FTIR), scanning electron microscopy (SEM), and the analytical parameters were optimized. The findings indicate that both drugs displayed clear oxidation peaks on the Gr-CPE and EDASP-CPE electrodes at pH 4.5 and 4.0, respectively, in the Britton-Robinson buffer. The linear dynamic range of ETV and TEV was determined between 1μM and 250μM on both working electrodes by DPV. The limit of detection (LOD) and limit of quantification (LOQ) for ETV were 0.2μM and 0.6μM, respectively, on Gr-CPE. The LOD and LOQ for TEV were 0.2μM and 0.7μM, respectively. The novel EDASP-CPE exhibited improved sensitivity with LOD and LOQ for ETV of 0.2μM and 0.5μM, respectively. The LOD and LOQ for TEV on EDASP CPE were 0.2μM and 0.7μM, respectively. The proposed method was successfully applied to the simultaneous determination of ETV and TEV in a commercial tablet dosage form, exhibiting good accuracy and precision. The results highlight the potential of the novel cross-linked ethylenediamine sulfonamide polymer resin-modified carbon paste electrode for the simultaneous determination of anti-HBV drugs in dosage form by differential pulse voltammetry.

Keywords

References

  1. [1] Asran AM, Mohamed MA, Ahmed N, Banks CE,Allam NK. An innovative electrochemical platform for the sensitive determination of the hepatitis B inhibitor Entecavir with ionic liquid as a mediator. J Mol Liq. 2020; 302: 112498. https://doi.org/10.1016/j.molliq.2020.112498
  2. [2] Guvenir M, Arikan A.Hepatitis B Virus: From Diagnosis to Treatment. Pol J Microbiol. 2020; 69(4): 391-399. https://doi.org/10.33073/pjm-2020-044
  3. [3] Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, Yu ML. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020; 73(1): 62-71. https://doi.org/10.1016/j.jhep.2020.01.027
  4. [4] Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020; 73(5): 1170-1218. https://doi.org/10.1016/j.jhep.2020.08.018
  5. [5] Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int. 2021; 41(10): 2341-2357. https://doi.org/10.1111/liv.14976
  6. [6] Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022; 14(2):434. https://doi.org/10.3390/v14020434
  7. [7] Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int. 2020; 40(S1):22-26. https://doi.org/10.1111/liv.14359
  8. [8] Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review article: Switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022; 55(8): 921-943. https://doi.org/10.3390/v12090998

Details

Primary Language

English

Subjects

Pharmaceutical Analytical Chemistry

Journal Section

Research Article

Publication Date

June 28, 2025

Submission Date

June 2, 2023

Acceptance Date

August 7, 2023

Published in Issue

Year 2024 Volume: 28 Number: 3

APA
Asfoor, A., Aydoğmuş, Z., & Senkal, B. (2025). Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry. Journal of Research in Pharmacy, 28(3), 579-602. https://izlik.org/JA74ZG95UL
AMA
1.Asfoor A, Aydoğmuş Z, Senkal B. Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry. J. Res. Pharm. 2025;28(3):579-602. https://izlik.org/JA74ZG95UL
Chicago
Asfoor, Adel, Zeynep Aydoğmuş, and Bahire Senkal. 2025. “Fabrication a Novel Ethylenediamine Sulfonamide Polymer Resin and Graphene-Modified Carbon Paste Electrodes for Simultaneous Determination of Anti-HBV Drugs Entecavir and Tenofovir in Dosage Form by Differential Pulse Voltammetry”. Journal of Research in Pharmacy 28 (3): 579-602. https://izlik.org/JA74ZG95UL.
EndNote
Asfoor A, Aydoğmuş Z, Senkal B (June 1, 2025) Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry. Journal of Research in Pharmacy 28 3 579–602.
IEEE
[1]A. Asfoor, Z. Aydoğmuş, and B. Senkal, “Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry”, J. Res. Pharm., vol. 28, no. 3, pp. 579–602, June 2025, [Online]. Available: https://izlik.org/JA74ZG95UL
ISNAD
Asfoor, Adel - Aydoğmuş, Zeynep - Senkal, Bahire. “Fabrication a Novel Ethylenediamine Sulfonamide Polymer Resin and Graphene-Modified Carbon Paste Electrodes for Simultaneous Determination of Anti-HBV Drugs Entecavir and Tenofovir in Dosage Form by Differential Pulse Voltammetry”. Journal of Research in Pharmacy 28/3 (June 1, 2025): 579-602. https://izlik.org/JA74ZG95UL.
JAMA
1.Asfoor A, Aydoğmuş Z, Senkal B. Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry. J. Res. Pharm. 2025;28:579–602.
MLA
Asfoor, Adel, et al. “Fabrication a Novel Ethylenediamine Sulfonamide Polymer Resin and Graphene-Modified Carbon Paste Electrodes for Simultaneous Determination of Anti-HBV Drugs Entecavir and Tenofovir in Dosage Form by Differential Pulse Voltammetry”. Journal of Research in Pharmacy, vol. 28, no. 3, June 2025, pp. 579-02, https://izlik.org/JA74ZG95UL.
Vancouver
1.Adel Asfoor, Zeynep Aydoğmuş, Bahire Senkal. Fabrication a novel ethylenediamine sulfonamide polymer resin and graphene-modified carbon paste electrodes for simultaneous determination of anti-HBV drugs entecavir and tenofovir in dosage form by differential pulse voltammetry. J. Res. Pharm. [Internet]. 2025 Jun. 1;28(3):579-602. Available from: https://izlik.org/JA74ZG95UL